Supernus Pharmaceuticals EBITDA Margin 2011-2024 | SUPN
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Supernus Pharmaceuticals (SUPN) over the last 10 years. The current EBITDA margin for Supernus Pharmaceuticals as of September 30, 2024 is .
| Supernus Pharmaceuticals EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-09-30 |
$0.65B |
$0.15B |
22.24% |
| 2024-06-30 |
$0.63B |
$0.11B |
17.94% |
| 2024-03-31 |
$0.60B |
$0.07B |
12.21% |
| 2023-12-31 |
$0.61B |
$0.08B |
12.99% |
| 2023-09-30 |
$0.61B |
$0.11B |
18.66% |
| 2023-06-30 |
$0.63B |
$0.11B |
16.88% |
| 2023-03-31 |
$0.67B |
$0.14B |
20.81% |
| 2022-12-31 |
$0.67B |
$0.14B |
20.54% |
| 2022-09-30 |
$0.66B |
$0.11B |
16.08% |
| 2022-06-30 |
$0.63B |
$0.13B |
20.32% |
| 2022-03-31 |
$0.60B |
$0.14B |
22.80% |
| 2021-12-31 |
$0.58B |
$0.14B |
23.49% |
| 2021-09-30 |
$0.56B |
$0.16B |
29.08% |
| 2021-06-30 |
$0.57B |
$0.18B |
32.05% |
| 2021-03-31 |
$0.56B |
$0.19B |
34.65% |
| 2020-12-31 |
$0.52B |
$0.21B |
39.54% |
| 2020-09-30 |
$0.48B |
$0.20B |
41.51% |
| 2020-06-30 |
$0.42B |
$0.18B |
41.98% |
| 2020-03-31 |
$0.40B |
$0.17B |
42.79% |
| 2019-12-31 |
$0.39B |
$0.17B |
42.60% |
| 2019-09-30 |
$0.41B |
$0.17B |
41.18% |
| 2019-06-30 |
$0.41B |
$0.17B |
40.83% |
| 2019-03-31 |
$0.40B |
$0.16B |
39.11% |
| 2018-12-31 |
$0.41B |
$0.16B |
39.61% |
| 2018-09-30 |
$0.38B |
$0.15B |
39.90% |
| 2018-06-30 |
$0.36B |
$0.14B |
37.99% |
| 2018-03-31 |
$0.33B |
$0.12B |
37.13% |
| 2017-12-31 |
$0.30B |
$0.11B |
35.43% |
| 2017-09-30 |
$0.28B |
$0.09B |
31.88% |
| 2017-06-30 |
$0.25B |
$0.08B |
32.41% |
| 2017-03-31 |
$0.23B |
$0.07B |
29.26% |
| 2016-12-31 |
$0.22B |
$0.06B |
26.51% |
| 2016-09-30 |
$0.20B |
$0.05B |
24.37% |
| 2016-06-30 |
$0.18B |
$0.03B |
18.44% |
| 2016-03-31 |
$0.16B |
$0.03B |
15.34% |
| 2015-12-31 |
$0.15B |
$0.02B |
14.86% |
| 2015-09-30 |
$0.14B |
$0.02B |
14.81% |
| 2015-06-30 |
$0.12B |
$0.01B |
11.76% |
| 2015-03-31 |
$0.11B |
$0.02B |
13.27% |
| 2014-12-31 |
$0.09B |
$-0.00B |
-2.15% |
| 2014-09-30 |
$0.07B |
$-0.02B |
-25.00% |
| 2014-06-30 |
$0.05B |
$-0.03B |
-68.00% |
| 2014-03-31 |
$0.02B |
$-0.05B |
-270.00% |
| 2013-12-31 |
$0.01B |
$-0.06B |
-536.36% |
| 2013-09-30 |
$0.00B |
$-0.06B |
-3050.00% |
| 2013-06-30 |
$0.00B |
$-0.06B |
-5700.00% |
| 2013-03-31 |
$0.00B |
$-0.05B |
-5100.00% |
| 2012-12-31 |
$0.00B |
$-0.04B |
-4100.00% |
| 2012-09-30 |
$0.00B |
$-0.04B |
inf% |
| 2012-06-30 |
$0.00B |
$-0.04B |
inf% |
| 2012-03-31 |
$0.00B |
$-0.04B |
-3600.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.000B |
$0.608B |
|
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
|
